drugset / Trial / NCT07100782
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Phase 3
Recruiting
130 enrolled
University of Michigan
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.
Timeline
- Start
- 2025-12-08
- Primary completion
- 2028-08
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Estradiol | Other / unclassified | 1 mg | — |
| Subject | Norethindrone | Unknown | 0.5 mg | — |
| Subject | Relugolix | Small molecule | 40 mg | — |